CJC-1295 5mg + Ipamorelin 5mg

Performance Profile

• Dual GH Axis Stimulation: Two GH-axis compounds combined: CJC-1295 (GHRH analogue) signals the pituitary to release GH, while Ipamorelin (GHRP) amplifies that signal at a separate receptor — stimulating the GH axis at two distinct points simultaneously.
• Lipolytic & Protein Synthesis Research: Preclinical models demonstrate effects on fat oxidation and muscle protein synthesis pathway signalling via GH axis modulation.
• Sleep Research: GH secretagogue influence on sleep architecture and associated biological processes has been studied in preclinical research models.
• GH-Mediated Tissue Research: Investigated for GH-mediated effects on dermal extracellular matrix composition and connective tissue biology.

Quick Summary

• Best For: GH axis research, dual secretagogue studies, pituitary biology.
• Use Case: Studying how stimulating the GH axis at two separate receptor sites changes GH secretion patterns compared to single-compound approaches.
• Research Note: The No DAC formulation produces a pulsatile GH release pattern — closer to the body’s natural rhythm — rather than a sustained elevated level.

For research purposes only. Not for human consumption. For use by licensed researchers only. These compounds have not been evaluated or approved by Health Canada for human use.